Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Binod Dhakal, Jesus G. Berdeja, Tara Gregory, Thomas Ly, Cara Bickers, Xingyue Zong, Lilly Wong, Jode P. Goodridge, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, John Byon, Rafat Abonour

Blood (2022) 140 (Supplement 1): 4586–4587.

https://doi.org/10.1182/blood-2022-166994

Published: 2022

Journal Articles

A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC-Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Mark Juckett, Sham Mailankody, Alireza Eghtedar, Cara Bickers, Xingyue Zong, Lilly Wong, Thomas Ly, John Byon, Sarah Cooley, Bahram Valamehr, Yu-Waye Chu, Ravi Vij

Blood (2022) 140 (Supplement 1): 10327–10328.

https://doi.org/10.1182/blood-2022-166728

Published: 2022

Journal Articles

Phase I Study of FT516, an Off-the-Shelf iPSC-Derived NK Cell Therapy, in Combination with Rituximab in Patients with Relapsed/Refractory B-Cell Lymphoma

Krish Patel, Veronika Bachanova, Aaron M Goodman, John M. Pagel, Kelly Griffis, Marlisa Anderson, Siminder Atwal, Cara Bickers, Peter Szabo, Lilly Wong, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati

Blood (2021) 138 (Supplement 1): 3873.

https://doi.org/10.1182/blood-2021-151520

Published: 2021

Journal Articles

Safety and Efficacy of FT596, a First-in-Class, Multi-Antigen Targeted, Off-the-Shelf, iPSC-Derived CD19 CAR NK Cell Therapy in Relapsed/Refractory B-Cell Lymphoma

Veronika Bachanova, Armin Ghobadi, Krish Patel, Jae H Park, Ian W. Flinn, Prutha Shah, Carol Wong, Cara Bickers, Peter Szabo, Lilly Wong, Bahram Valamehr, Siminder Atwal, Yu-Waye Chu, Rebecca Elstrom, Paolo Strati

Blood (2021) 138 (Supplement 1): 823.

https://doi.org/10.1182/blood-2021-151185

Published: 2021